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Abstract Pulmonary metastasectomy for colorectal cancer is
commonplace surgery, but the practice has grown on the basis
of follow-up studies. These studies base their conclusion on
the effectiveness of metastasectomy on the survival rates at 5
years of very highly selected patients. Three publications in
the last year, a registry study, a meta-analysis and a
randomised controlled trial of monitoring and early detection
of cancer recurrence, prompted a review of the evidence. A
critical examination of the evidence suggests that much of the
apparent benefit may be due to selection of patients most
likely to survive on the basis of well-known prognostic fea-
tures, explicitly stated in the clinical record. Clinicians also
assess their patients over time and do not offer surgery to those
with faster progression. Such clinical judgements are of their
nature often subtle and undocumented and thus cannot be
retrieved from the clinical record. Although some patients
may have long survival following pulmonarymetastasectomy,
and indeed their survival might be believed to be due to
resection of pulmonary metastases, how many patients must
be operated on to find these survivors? What is the number
‘needed to treat’? It may be that of the patients having
metastasectomy, for the greater proportion it does not materi-
ally alter their survival. A randomised controlled trial to
resolve this uncertainty is in progress. The Pulmonary
Metastasectomy in Colorectal Cancer (PulMiCC) trial is
recruiting in Britain and Europe.
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Introduction
After potentially curative surgery for colorectal cancer, a
policy of monitoring patients for asymptomatic recurrence is
the standard of care [1, 2]. Detection of recurrence is accom-
plished by measurement of carcinoembryonic antigen (CEA)
and imaging with whole-body CT. This permits early detec-
tion of liver and or lung metastasis so that they can be
evaluated for resection with intention to cure.
In 2007, the present author, who was receiving an increas-
ing number of referrals to perform surgery for which there was
no good evidence, challenged the effectiveness of pulmonary
metastasectomy [3]. At about the same time, the European
Society of Thoracic Surgeons (ESTS) opened its Lung
Metastasectomy Project. When the Working Group reported
in 2010, its leaders concluded ‘the level of evidence to support
current practice is too low to set firm recommendations to the
members of ESTS. In the absence of a randomized controlled
tr ia l looking at the effec t iveness of pulmonary
metastasectomy on survival and quality of life, it is unlikely
that the current practice will ever be influenced.’
This led to the Pulmonary Metastasectomy in Colorectal
Cancer (PulMiCC) randomised controlled trial (RCT), now
recruiting in Britain and Europe [4].
Three articles published within the last year underline in
different ways the continuing and now pressing need for better
evidence.
1. A systematic review of 25 studies published from 2000 to
2011 provides a meta-analysis of 2,925 patients who had
pulmonary metastasectomy. The three well-established
prognostic factors (more than one metastasis; an interval
since primary resection of under 2–3 years; elevated CEA
level) each approximately double the likelihood of early
progression of disseminated disease after pulmonary
metastasectomy [5••].
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2. A population-based study of 543 patients, estimated to
include about 60% of patients having pulmonary
metastasectomy in Spain in a 2-year period from 2008
to 2010, provides the first prospective study of practice
[6••]. Of these patients, 45% had multiple metastases, half
had intervals of under 28 months and CEA level was
elevated in 46%. Many of these patients are therefore in
the categories where the disease will progress irrespective
of the metastasectomy.
3. An RCT involving 1,202 patients, the Follow-up After
Colorectal Surgery (FACS) trial, found that intensive
CEA and/or CT monitoring does detect metastatic cancer
earlier than minimum follow-up, but the ensuing surgery
did not result in any increased survival comparedwith that
of patients in whom the metastatic disease remained un-
discovered [7••].
Wide acceptance that metastasectomy is effective in im-
proving survival is based on numerous follow-up studies of
highly selected patients. Randomised trials, control data and
intention-to-treat analysis are lacking. An analysis of the how
oncologists and surgeons arrived at their belief in the effec-
tiveness of metastasectomy is the subject of this review.
The Evidence for Pulmonary Metastasectomy
in Colorectal Cancer
There must now be over 100 follow-up studies, and they are
still being submitted for publication. Amongst them there
have been numerousmultivariate analyses, including the land-
mark report of the International Registry of Lung Metastases
[8]. There were three systematic reviews of pulmonary
metastasectomy in colorectal cancer between 2007 and 2010
[9–11]. They are mutually consistent in their findings and are
consistent with the most recent systematic review and meta-
analysis reported in 2013.
In the meta-analysis, four factors were associated with
shorter survival time after lung metastasectomy:
1. For patients with multiple lung metastases compared with
a solitary metastasis, there was a hazard ratio (HR) of 2.04
[95 % confidence interval (CI) 1.72–2.41]. Having more
than a solitary metastasis doubles the likelihood of dying
within 5 years.
2. Elevated prethoracotomy CEA level nearly doubles the
likelihood of dying within 5 years (HR 1.91; 95 % CI
1.57–2.32).
3. A ‘disease-free’ interval shorter than 2–3 years between
the primary operation and lung metastasectomy increases
by about 60% the likelihood of dying within 5 years. (HR
1.59, 95 % CI 1.27–1.98).
4. Positive hilar and/or mediastinal lymph nodes also in-
crease the likelihood of dying within 5 years by about
60% (HR 1.65, 95 % CI 1.35–2.02).
No doubt aware of the potential for confusion, the Journal
of Thoracic Oncology published a biostatistics primer for
‘what clinicians ought to know’ setting out the difference
between prognostic and predictive factors: ‘A prognostic fac-
tor is a variable that is assessed before starting any treatment;
based on the value of this factor, the clinician can expect that a
patient may have a better or worse clinical outcome (such as
survival or response), regardless of what treatment the patient
receives’ [12].
It is important to remember that the first three factors are
general prognostic factors, as is the third if the information is
available before the metastasectomy [12].
It is impressive that these factors remain so powerful in the
analysis of Gonzalez et al. [6••] because these have been well
known for many years and operated-on patients were highly
selected in the full knowledge of these factors. For them to
emerge from an analysis with these HRs suggests that they are
commonly overridden, as they were in the Spanish study [6••].
The authors of the meta-analysis, in their discussion, take the
view that ‘as long as a R0 resection is feasible, it seems
currently unfair to deny surgery for those patients with two
to four lesions’, which reflects current beliefs in practice rather
than being a conclusion that can be derived from the data [5••].
The fourth factor, the evidence of further dissemination
from the lung metastasis to hilar and mediastinal nodes, is in
these series usually a pathology finding because it would be
unlikely and indeed irresponsible to knowingly operate on
such patients. Metastasectomy is likely to be ineffective if
patients have already further dissemination via the pulmonary
lymphatics. The operation is doomed to fail in its objective to
achieve R0 resection. Although it has been proposed that
mediastinoscopy should precede pulmonary metastasectomy
[13], we cannot know how many patients have mediastinal
staging investigations because reports are always of patients
who have had metastasectomy, and they do not tell us any-
thing of the selection process.
Many studies go as far as to exclude patients who did not
have histological confirmation of R0 resection [9, 10], thus
further defeating any attempt to understand the outcomes on
the basis of ‘intention to treat’, which is the information that
should be put to patients when metastasectomy is being
discussed with them. This illustrates one of the many pitfalls
in the custom and practice of surgical follow-up studies as a
means of reporting results of surgery and the impossibility of
drawing reliable inferences from them [14].
Amongst the systematic reviews was a quantitative synthe-
sis of 3,504 patients in 51 studies reported from 1971 to 2007
[11]. This revealed that that although the practice had grown,
the case mix had been remarkably consistent over about four
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decades. In round figures, 60% of metastasectomy operations
were for a solitary metastases, the interval averaged 36months
and 60% of patients had died within 5 years.
Pulmonary Metastasectomy as Palliation
There are few data on symptoms in any of these follow-up
studies. [11]. Most patients having pulmonary metastasectomy
are asymptomatic with respect to colorectal cancer. Occasion-
ally, a pulmonary metastasis may cause symptoms (cough,
haemoptysis, pain, etc.), and then surgery is assessed on an
individualised basis.
At the terminal phase of the disease, there is not usually a
pulmonary component to the symptoms or mode of death
which might have been prevented by surgery. The policy of
seeking out and resecting metastases is therefore not palliative
in any sense.
Selection or Surgery as the Determinant of Survival
Reporting a small comparative study of pulmonary
metastasectomy in 1980, Åberg et al. [15] wrote: ‘It has been
assumed, implied, or claimed that the 5-year survival without
operation is nil. Control material is, however, lacking.’
Both sentences remain true 34 years later: it is widely
believed that any 5-year survivors after pulmonary
metastasectomy can thank the operation for their survival,
but there are no control data. The best estimates of the degree
of selection in the Spanish study [6••] is that these are fewer
than 5% of metastatic colorectal cancer patients, and estimates
from Italian and Japanese studies indicate that the rates may be
around 2–3%, but the appropriate denominator is hard
determine.
The assumption that survival at 5 years, were it not for lung
metastasectomy, approaches zero is false. Data from the
Thames Cancer Registry show that for patients with metasta-
ses at presentation (stage 4 in its terminology), the 5 and 10-
year survival rates were 10% and 5%, respectively. We can
consider the implications of these data in selection. We have
known for years the characteristic of patients who have longer
survival after metastasectomy. Clinicians caring for these pa-
tients have had, in addition, ample opportunity to review
imaging to look at the number of metastases and their appear-
ance and growth over time. So patients in follow-up studies
were not only selected on the basis of the explicit criteria
retrievable from the records but were further selected in full
knowledge of their progression over time. This is probably the
most powerful determinant of whether they will be alive some
years later, and it might well be that the selected minority of
patients will contain the natural survivors. A selection of 100
of 1,000 patients might include the 50 destined to live longer,
and the resulting 50% survival is thus easily explained. We
cannot capture this process from follow-up studies, and we
must surely realise that the gap between survival without and
with lung metastasectomy is not the difference between 0 and
50%.
It should also be remembered that the process of selection
has as its precondition that the patient must have survived to
the time point of being considered for metastasectomy and
therefore includes immortal time bias [16–18]. This is partic-
ularly true if, for example, responsiveness to chemotherapy is
included in selection, and is particularly illustrated by appar-
ently favourable results of second and third metastasectomy.
There is a large conditional component of having already
survived to the time point for a patient to be included in the
cohorts having repeated metastasectomy.
The Thames Cancer Registry data were used tomodel what
might have been the 5-year survival rates for patients in two
large follow-up studies [19, 20]. Survival curves were con-
structed for registry patients with a similar mix of cancer
stages at registration and who remained alive for a period
similar to the ‘disease-free interval’ in the published follow-
up studies. The two 5-year survival rates were similar [21].
For more readily accessible accounts of this study, see the
subsequent articles in which it is used [22, 23] (Table 1).
How can this be? From their recollections, clinicians de-
fend their practice in the belief that formerly no such patients
survived beyond 1 year or so and that now they see long-term
survivors. It would not be the first time that the clinical
impressions of committed and dedicated clinicians are not
supported by evidence when they are put to a fair test [24].
Patients are selected for surgery on the basis of many factors,
including the trajectory of their clinical state over a period, a
feature that is not captured in surgical follow-up studies. The
authors rely on the limited information recorded at a point in
time when the decision was taken to perform metastasectomy.
Back at the time of selection, the rate of progression is evident
to clinicians, and those patients progressing are unlikely to
appear in the operating theatre.
How the Literature and the Belief in It Grew
In the course of our studies of pulmonary metastasectomy, we
became aware of the fascinating method of citation network
analysis [25]. Greenberg [25] proposed that ‘citation can be
used to generate information cascades resulting in unfounded
authority of claims’.
The citation lists of the 51 follow-up studies used in the
quantitative synthesis [11] were used to analyse the nature of
the evidence on which those authors themselves had relied in
writing up their follow-up studies [26].
What we discovered was frenzy of mutual citation amongst
authors with shared beliefs. (Fig. 1). We confirmed Greenberg’s
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statement that ‘unfounded authority was established by citation
bias against papers that refuted or weakened the belief;
amplification, the marked expansion of the belief system
by papers presenting no data addressing it; and forms of
invention such as the conversion of hypothesis into fact
through citation alone.’
The article by Åberg et al. [15] formally challenging the
belief in metastasectomy reporting the only, albeit small,
comparative study was cited twice. A case report buried
within a 1944 ‘state of the art’ lecture to the Boston Medical
Society concerning progress in thoracic surgery [27] was cited
by 14 of 51 of the index papers, and is the thirteenth most
frequent of 334 cited papers. The article by Åberg et al. is
directly relevant, and would show up in any search including
the word ‘metastasectomy’. The article by Blalock [27] has no
relevance to the practice and can only have been passed on
from author to author; it would not have been found in a
literature search. There is no clue in the title, and the tenuous
connection with practice would take some perseverance to
discover if indeed the article had been read at all. The cascade
effect is ‘like rolling a snowball: it gets bigger and bigger – but
it is just more snow’ [26].
The practice of monitoring patients by means of their CEA
level grew in the 1970s and 1980s, and was the basis of an RCT
to determine if the earlier detection that it allowed, before the
presence of symptoms, would result in better survival. The
study recruited patients from 1982 to 1993. There was no
benefit, but instead a small excess of deaths in those randomised
to have CEA monitoring prompted second-look surgery (91 of
108 versus 88 of 108; difference 2.8%) [28]. The reporting of
the results of the trial lapsed in 1994, perhaps perceived to have
been overtaken by events. As part of the initiative to restore
invisible and abandoned trials [29, 30], the full results have
been published [31]. The FACS trial asked the same question
and returned the same answer in 2014. For 901 patients
randomised to have CEAmonitoring, CTor both, the mortality
was 18.2%, whereas for those having symptom-prompted in-
vestigations and clinical follow-up, the mortality was 15.9%, a
difference of 2.3%, similar to that found in 1994 favouring
patients spared unavailing second-look surgery (Table 2).
Table 1 Reported and modelled 2-year survival
Authors Date Patients Reported 5-year survival rate (%)a Modelled 5-year survival rate (%)
McCormack et al. [19] 1992 144 40 (32-48) 55
Okumura et al.[20] 1996 159 41 (33-48) 50
Amathematical modelling study [21] in which Thames Cancer Registry survival data were used to construct survival analysis for groups of patients with
a Dukes stage similar to that of patients in the surgical follow-up studies and still alive at 36 months, which was the average interval from primary to
metastasectomy operation to exclude patients who had not survived long enough to have become candidates for pulmonary metastasectomy
a The 95 % confidence interval is given in parentheses
Fig. 1 This graphic is from a
network analysis in which nodes
1–51 are the follow-up studies of
lung metastasectomy for
colorectal cancer in the
quantitative synthesis, and the
remaining nodes, to a total of 72,
are colorectal cancer studies
which are cited. The article by
Åberg et al. [15] questioning the
effectiveness of lung
metastasectomy is cited only
twice, whereas there appears to be
a feeding frenzy of mutual
citation amongst the believers.
(From Fiorentino et al. [26], with
permission from Nature
Publishing Group)
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Oligometastasis and Ablative Therapies
Minimally invasive therapies such as radiofrequency ablation
(RFA) and stereotactic radiotherapy can destroy tissues accurately
and reliably without the need for open surgery. They have a very
valuable role in treating symptomatic lesions where the evidence
of effectiveness is basically the N of one trial. In comparisonwith
surgery, they are proposed as an alternative to metastasectomy,
being safer and less invasive. However, the arguments rest on a
prior belief that surveillance and eradication of asymptomatic
metastases improves survival, which has been shown not to be
the case [7••]. If we are unsure of the effectiveness of surgery in
this regard, effectiveness of less invasive ablation must be tested
in its own right. This has been done for colorectal liver metasta-
ses. There was no difference in survival between those patients
who had and those patients who did not have RFA in this RCT
[32•]. On the basis of the only RCTevidence available, RFAwas
thus ineffective in improving survival.
The oligometastatic state, a term coined by radiation ther-
apists [33] and now in the argot of cancer teams and tumour
boards, has shaky evidence. It is a concept without empirical
evidence. The ‘fewness’ of metastases is no doubt a reflection
of the biological nature of that individual’s cancer: the more
metastases, the more aggressive the cancer, and the converse
is a necessary corollary. There is no suggestion that the distri-
bution of the number of metastases is bimodal, which would
be expected if the oligometastatic state were a pathological
entity. It is no more than an arbitrary convention to give some
identity to what is nomore than a therapeutic opportunity [34].
To define a disease by the therapy available and that would be
needed to treat it is perfectly reasonable and is standard, for
example, in end stage renal disease [35, 36], but the treatment
should still be proven to be effective.
Conclusions
We know that of al l patients having pulmonary
metastasectomy, most go on to die of their colorectal cancer.
Of all patients with pulmonary metastases, only 2-3% have
pulmonary metastasectomy, and of this highly select group,
authors further select subsets in whom there were high 5-year
survival rates. But how many are ‘cured’? Or is it that this
process of selection on selection simply identifies the minority
with slowly progressing disease?
It is the view of the author that pulmonary metastasectomy
is offered to patients without adequate evidence. There are
many historical precedents for reversals in practice and belief.
The PulMiCC RCT is in progress and will provide the first
controlled data to guide future practice.
The PulMiCC trial design is based on the premise that of
patients with lung-only or liver and lung metastases many will
be not be offered metastasectomy. At the other end of the
spectrum of adverse to favourable features are the patients that
most teams will consider for metastasectomy. It follows that if
there is a ‘no’ for some and ‘yes’ for others, there must be a
transitional zone of uncertainty. It is only in that zone, and it
varies between the more conservative and the more aggressive
team, that randomisation is invited in the second stage of the
recruitment process. However, all patients can be recruited
into the first stage.
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Table 2 How the evidence for metastasectomy for colorectal cancer was
overtaken by events: the history of adoption of liver resection for colo-
rectal metastasectomy is documented by Grunhagen et al. [37]
Date Publication
1954 Wangensteen et al. [38] advocated second-look surgery in
asymptomatic patients following colorectal cancer
1971–1978 Resection of recurrent cancer after potentially curative
resection of colorectal cancer was believed sometimes
to lead to ‘cure’ [39–41]
1974–1980 CEA monitoring was shown to detect asymptomatic
recurrence of colorectal cancer following surgery, with
the possibility of better results for second-look surgery
[42–46]
1981 NIH consensus call for a trial of CEA monitoring [47]
1982 The CEA Second-Look trial started recruiting [31]
1982–1989 Hughes et al. [48–51] published registry results of liver
resection with increasing numbers
1990–1991 Scheele et al. [52–54] published a growing institutional
cohort of liver resections
1992 McCormack et al. [19] published 10-year results of
pulmonary metastasectomy in colorectal cancer
1992 Rosen et al. [55] published the power calculation for a
randomised trial of liver resection. Claims for benefit
versus natural history were so far apart that, if correct,
36 patients would have been sufficient to prove it
1994 CEA Second-Look Trial results available [28, 56]
1994 Stangl et al. [57] wrote ‘benefit … has been clearly
demonstrated’
1994 Scheele et al. [58] wrote ‘trials on … effectiveness of
hepatic resection for metastatic colorectal cancer
[would be] not only obsolete but unethical’
1997 The International Registry of Lung Metastases reported
its analysis of prognostic factors for lung
metastasectomy [8]
CEA carcinoembryonic antigen, NIH National Institutes of Health
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